In a significant advancement for alcohol metabolism management, Quantum BioPharma (NASDAQ: QNTM) has announced positive results from a recently completed clinical trial for its dietary supplement UnbuzzdTM. The study demonstrated remarkable efficacy in accelerating alcohol metabolism and reducing intoxication symptoms.
Clinical Trial Results
The double-blind, placebo-controlled study revealed that UnbuzzdTM significantly enhanced alcohol metabolism, reducing blood alcohol concentration by more than 40% within 30 minutes compared to placebo. Beyond alcohol metabolism, the supplement showed additional beneficial effects, including improved alertness and stabilization of cardiovascular parameters such as heart rate and blood pressure.
"UnbuzzdTM represents a breakthrough in promoting safe and responsible alcohol consumption," stated Quantum BioPharma CEO Zeeshan Saeed. The trial participants reported notable improvements in common alcohol-related issues, experiencing reduced mental fatigue and decreased hangover symptoms, with no observed adverse effects.
Strategic Commercial Partnership
While maintaining its focus on pharmaceutical development, Quantum BioPharma has established a strategic partnership with Celly Nutrition Corp. for the over-the-counter distribution of UnbuzzdTM. The agreement includes a 7% royalty on sales until reaching $250 million in payments to Quantum BioPharma, after which it converts to a 3% perpetual royalty. Notably, Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and maintains exclusive rights for pharmaceutical and medical applications of similar products.
Broader Corporate Focus
Beyond UnbuzzdTM, Quantum BioPharma continues to advance its neurodegenerative disease portfolio through its subsidiary, Lucid Psycheceuticals Inc. The company's lead compound, Lucid-MS, has shown promise in preclinical models for multiple sclerosis treatment by preventing and reversing myelin degradation, demonstrating the company's commitment to addressing various medical challenges.
